Hematologic Oncology | Specialty

The OncLive Hematology Oncology condition center page is a comprehensive resource for clinical news and expert insights on various hematologic malignancies, including leukemias, lymphomas, myeloproliferative neoplasms, multiple myeloma, and much more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in hematologic cancers.

KD025 Induces Impressive Activity in cGVHD

February 25th 2020

The selective ROCK2 inhibitor KD025 induced clinical responses in approximately two-thirds of patients with chronic graft-versus-host disease, including complete responses in 3 patients.

CAR-T Leads Advances Across Lymphomas, But Further Research Needed

February 25th 2020

Dimitrios Tzachanis, MD, PhD, discusses updates and remaining questions with CAR T-cell therapy.

Novel Approaches Under Exploration Across Lymphoma Subtypes

February 24th 2020

Erin Reid, MD, discusses the treatment advances across lymphomas and the remaining questions that need to be answered with further research.

Pasireotide Does Not Decrease Risk of GI Toxicity or Acute GVHD Following HSCT

February 24th 2020

Anthony D. Sung, MD, discusses the findings from the phase II trial of pasireotide as a method to prevent gastrointestinal toxicity and acute graft-versus-host-disease in patients who undergo allogeneic hematopoietic stem cell transplant.

Narsoplimab Emerging as Treatment Option for TA-TMA

February 23rd 2020

Narsoplimab (OMS721) is advancing through the therapy pipeline as a novel treatment option for patients with transplant-associated thrombotic microangiopathy.

"Off-the-Shelf" CAR T-Cell Therapy Shows Promise in Non-Hodgkin Lymphoma

February 22nd 2020

An “off-the-shelf” Epstein Barr-virus–specific cytotoxic lymphocyte CAR product derived from cells harvested from third-party donors induced a 100% response rate in adult and pediatric patients with relapsed/refractory non-Hodgkin lymphoma.

Expert Highlights Remaining Diagnostic Challenges With TA-TMA

February 22nd 2020

Sergio A. Giralt, MD, discusses the diagnostic challenges of transplant-associated thrombotic microangiopathy.

Conditioning Therapy With Iomab-B Leads to High Transplant Rate in Active AML

February 21st 2020

Iodine (131I) apamistamab (Iomab-B) conditioning induced a complete remission in 84% (31/38) of patients with active acute myeloid leukemia, who were then able to receive allogeneic hematopoietic stem cell transplant, according to preliminary results from the phase III SIERRA trial.

Targeted Approaches Under Exploration in Peripheral T-Cell Lymphoma

February 21st 2020

Aaron Goodman, MD, discusses recent changes to the frontline treatment of patients with peripheral T-cell lymphoma and the challenges of targeting T-cell lymphoma.

Dr. Tan on the Risk of Novel Coronavirus for Patients With Cancer

February 21st 2020

Christina Tan, MD, MPH, discusses the potential impact of the novel coronavirus on patients with cancer.

Dr. Heyman on Frontline Treatment Options in Follicular Lymphoma

February 21st 2020

Benjamin Heyman, MD, discusses frontline treatment options for patients with follicular lymphoma.

Ruxolitinib Efficacy in Chronic GVHD Highlighted Across Age Groups

February 21st 2020

Ruxolitinib is an effective and well-tolerated treatment in the refractory setting for patients with chronic graft-versus-host disease, regardless of age.

Liso-Cel Analysis Shows Feasibility of Outpatient CAR T-Cell Therapy

February 20th 2020

Outpatient administration of CAR T-Cell therapy is safe and effective, according to an analysis of 3 studies of lisocabtagene maraleucel in patients with relapsed/refractory large B-cell lymphoma.

Bendamustine Plus Rituximab Shows Promise as Induction Therapy in Mantle Cell Lymphoma

February 20th 2020

Diego Villa, MD, MPH, discusses the benefit of bendamustine and rituximab versus R-CHOP in transplant-eligible and -ineligible patients with mantle cell lymphoma.

Isatuximab Shows Promise in Relapsed/Refractory Multiple Myeloma

February 20th 2020

Joseph Mikhael, MD, discusses isatuximab in the context of recent, promising data from the ICARIA-MM trial in relapsed/ refractory multiple myeloma.

FDA Grants Priority Review to Selinexor for Relapsed/Refractory DLBCL

February 20th 2020

The FDA has granted a priority review designation to a supplemental new drug application for selinexor as a treatment for adult patients with relapsed/refractory diffuse large B-cell lymphoma, not otherwise specified, who have received ≥2 prior therapies.

FDA Issues Complete Response Letter for Updated Pembrolizumab Dosing Schedule

February 20th 2020

The FDA has issued a complete response letter to 6 supplemental biologics license applications that would have updated the dosing schedule for pembrolizumab to include an every-6-weeks option at 400 mg over 30-minute infusions across multiple indications.

Dr. Pasquini on Tisagenlecleucel in Real-World and Clinical Trial Settings in ALL and DLBCL

February 19th 2020

Marcelo Pasquini, MD, discusses the similarities between real-world experience with tisagenlecleucel and in the ELIANA and JULIET trials.

Dr. Patel on the Role of Gilteritinib in FLT3+ AML

February 18th 2020

Prapti Patel, MD, discusses the role of gilteritinib in patients with FLT3-mutated acute myeloid leukemia.

FDA Grants Priority Review to Tazemetostat in Follicular Lymphoma

February 14th 2020

The FDA has granted a priority review designation to a supplemental new drug application for tazemetostat for the treatment of patients with relapsed/refractory follicular lymphoma who have received at least 2 prior lines of systemic therapy.